Small Molecule Prefilled Syringes Market SWOT Analysis Report 2021-2028 | Sanofi, Viatris, AstraZeneca Plc, F. Hoffmann-La Roche AG

Availability of a wide variety of products for small molecule prefilled syringe products (branded and generic), benefits over conventional forms of dosage forms (instant effect) including capsules and tablets, and rising acceptance of products of small molecule prefilled syringe is expected to drive the global small molecule prefilled syringes market growth over the forecast period. Players are focused on capitalization of patent losses for launching generic versions into the global small molecule prefilled syringes market.

Request Sample Report + Related Graphs & Charts @:
https://www.coherentmarketinsights.com/insight/request-sample/1629

Key Players in This Report Include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, and Fresenius Kabi AG.

For instance, Mylan N.V., in 2017, launched the generic alternative for Copaxone 40 mg/ml for the patients of multiple sclerosis in the U.S. Furthermore, Mylan N.V. introduced Brabio, the first generic substitute of Copaxone 40 mg/ml, for patients of multiple sclerosis in January 2018, in the U.K. Teva Pharmaceuticals improved its presence within Multiple Sclerosis segment by introducing three-times-a-week product of Copaxone 40 mg/mL in 2014 in the U.S. Teva Pharmaceuticals, in 2015, introduced Generic Lovenox within the U.S. market.

Fresenius Kabi, in 2016, launched the injection within its prefilled glass syringe which is ready-to-administer. Sandoz, in February 2018, announced the approval of the U.S. Food & Drug Administration and launch for Glatopa (Glatiramer acetate) 40 mg/mL.

Request for customization in Report @ https://www.coherentmarketinsights.com/insight/request-customization/1629

Key market players are focused on acquisitions, partnerships, and collaborations, for enhancing their share in the global small molecule prefilled syringes market. For instance, Unilife Corporation, in 2013, entered in a contract of long-term supply with Sanofi S.A. This contract was aimed at using Unifill Finesse platform from Unilife for prefilled syringes with the Enoxaparin Sodium by Sanofi S.A. sold under the brand names, Clexane and Lovenox.

In 2015, Hospira, Inc. was acquired by Pfizer, Inc. The Hospira, Inc. was the leading supplier of infusion technologies and injectable drugs, which is expected to drive the company for enhancing the market share. Fresenius Kabi USA, in 2016, acquired Becton, Dickinson, and Company’s BD Rx business. This business consisted pharmaceutical manufacturing facility and the line consisting seven drugs -BD Simplist in prefilled glass syringes that are ready-to-administer.

Small Molecule Prefilled Syringes Market: Key Takeaways

• The global small molecule prefilled syringes market is expected to witness a 6% CAGR of during the forecast period (2017–2025), due to rising product launches from manufacturers including Mylan N.V., Fresenius Kabi, AG, and others in the prefilled syringes

• Small molecule therapy availability in the neurology segment is extremely low and hence, which is expected to drive growth of this segment

• Majority drugs in neurology drugs segment including Copaxone (produced by Teva Pharmaceutical Industries Ltd.) is expected to encounter competition by generics

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/1629

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.